论文部分内容阅读
目的:观察代谢综合征患者真胰岛素水平,了解其临床意义,并评价糖尿病组与非糖尿病组的差异。方法:正常对照组100例;代谢综合征组200例,其中糖尿病组142例,非糖尿病组58例。采用化学发光免疫分析法检测空腹真胰岛素(FTI),采用全自动生化分析仪检测空腹血糖(FBG),计算胰岛素抵抗指数。结果:代谢综合征患者血清FTI浓度与正常人比较,差异无统计学意义(P>0.05)。代谢综合征患者胰岛素抵抗指数(HOMA-IR)明显高于正常对照组(P<0.01)。糖尿病组胰岛素抵抗指数明显高于非糖尿病组(P<0.01)。结论:特异性测定血中的胰岛素水平能更真实的反映患者的胰岛素水平。代谢综合征患者存在胰岛素抵抗,代谢综合征糖尿病组胰岛素抵抗明显高于非糖尿病组。
Objective: To observe the true insulin in patients with metabolic syndrome, to understand the clinical significance, and to evaluate the difference between diabetic and non-diabetic patients. Methods: 100 cases of normal control group and 200 cases of metabolic syndrome group, including 142 cases of diabetic group and 58 cases of non-diabetic group. Fasting true insulin (FTI) was detected by chemiluminescence immunoassay. Fasting blood glucose (FBG) was measured by automatic biochemical analyzer. Insulin resistance index was calculated. Results: There was no significant difference in serum FTI concentration between patients with metabolic syndrome and normal controls (P> 0.05). Insulin resistance index (HOMA-IR) in patients with metabolic syndrome was significantly higher than that in the normal control group (P <0.01). Insulin resistance index in diabetic group was significantly higher than that in non-diabetic group (P <0.01). CONCLUSIONS: Specificity determination of blood insulin levels more accurately reflects the patient’s insulin level. Insulin resistance exists in patients with metabolic syndrome, insulin resistance in the metabolic syndrome diabetic group is significantly higher than non-diabetic group.